Drug Ther Bull. 2014 Jul;52(7):81-4. doi: 10.1136/dtb.2014.7.0267.
▼Teriflunomide (Aubagio-Genzyme Therapeutics), the main metabolite of the disease-modifying anti-rheumatic drug leflunomide,1 is an immunomodulatory agent with anti-inflammatory properties.2 It is a new oral treatment licensed for adults with relapsing-remitting multiple sclerosis. Here we discuss the evidence for its effectiveness and safety, and consider its place in therapy.
▼特立氟胺(奥巴捷-健赞公司)是疾病修饰抗风湿药物来氟米特的主要代谢产物,1 是一种具有抗炎特性的免疫调节剂。2 它是一种新的口服药物,已获许可用于复发缓解型多发性硬化症的成人患者。在此,我们讨论其有效性和安全性的证据,并探讨其在治疗中的地位。